The company’s shares closed yesterday at $14.92. Samimy covers the Healthcare sector, focusing on stocks such as Jazz Pharmaceuticals, Viking Therapeutics, and Apellis Pharmaceuticals. According to ...
Suvannavejh covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Apellis Pharmaceuticals, and Corbus Pharmaceuticals. Neumora Therapeutics, Inc. has an analyst consensus of ...
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price target decreased by Bank of America from $61.00 to $47.00 ...
Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 ...
Wells Fargo lowered the firm’s price target on Apellis (APLS) to $30 from $43 and keeps an Equal Weight rating on the shares. The firm thinks Q3 was validating for its view of a slowing GA ...
Two pioneering digital therapeutics (DTx) for addiction are available once again after their original developer Pear Therapeutics was dissolved last year. The AI effect in pharma commercial ...
Sanofi S.A. Part Cert 0.06% €8.19M ...
Dyne Therapeutics Inc.-2.70% $2.94B ...
Apellis Pharma and partner Sobi have won EU approval for their paroxysmal nocturnal haemoglobinuria (PNH) drug pegcetacoplan in Europe, with a more restricted label than in the US. The European ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback